Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)

N/A Active, not recruiting NCT01385176

Condition	Heart Failure, Congestive Heart Failure
Phase	N/A
Sponsor	Boston Scientific Corporation
Status	Active, not recruiting
Enrollment	118 participants
Interventions	Implant of investigational device system, Titration during the randomization phase, Titration after the randomization phase, Blood Draw
Start date	Sep 21, 2011
Completion date	May, 2014
Results posted	Jan 6, 2020

Summary

The NECTAR-HF feasibility trial is designed to evaluate the application of right vagal nerve stimulation in heart failure patients with a New York Heart Association Class III, an ejection fraction equal to or less than 35 %, and a narrow QRS duration equal to or less than 130 ms.

Change in Left Ventricular End-systolic Dimension (LVESD)

LVESD at Baseline and at 6-months post Baseline · cm

Therapy	-0.04 ± 0.25 cm
Control	-0.08 ± 0.32 cm

Percentage of Surviving Participants

18-months · Percentage of participants surving

All Patients in Active VNS Periods	95 Percentage of participants surving

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

Implantation of a Permanent Interatrial Shunt to Reduce Left Atrial Filling Pressures Foll — samir kapadia
Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant — University of Utah
Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure — Yale University
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using th — Boston Children's Hospital
PROACTIVE-HF IDE Trial Heart Failure NYHA Class III — Endotronix, Inc.
Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coord — Weill Medical College of Cornell University

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский